Form 8-K RESMED INC For: Jan 24

Go back to Form 8-K RESMED INC For: Jan 24

JPMorgan Downgrades ResMed (RMD:AU) (RMD) to Underweight

January 25, 2019 7:10 AM EST

JPMorgan analyst David Low downgraded ResMed (RMD:AU) (NYSE: RMD) from Neutral to Underweight with a price target of AUD13.40.

Low notes results were boosted by a one-off benefit. Sales will likely be subdued over much of 2019 as the business cycles... More

Goldman Sachs Downgrades ResMed (RMD:AU) (RMD) to Neutral

January 25, 2019 7:01 AM EST

Goldman Sachs analyst Chris Cooper downgraded ResMed (RMD:AU) (NYSE: RMD) from Buy to Neutral with a price target of AUD15.20 (from AUD16.70).

Cooper said shares were priced for perfection going into the 2Q print and the company delivered a meaningful 3% sales... More